Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Regulatory agencies have highlighted the value of patient-reported outcome (PRO) endpoints in understanding treatment benefit. However, interpreting statistically significant health-related quality of life (HRQoL) benefits of new treatments can be challenging. Although the original scoring approaches must be used in trials, it may also be useful to generate complementary, intuitive metrics for PRO instruments that are easier to interpret by non-experts.
Several health-related and professional organizations have developed frameworks to assess the value of oncology drugs in a systematic and transparent manner. This research intends to identify such tools and gain a better understanding of their similarities and differences.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
